EQUECABTAGENE AUTOLEUCEL (CT053): CHINA'S
DOMESTICALLY APPROVED MYELOMA CAR-T

Equecabtagene autoleucel is a CAR-T cell product made from the patient's own T cells. The cells are collected through leukapheresis, sent to the manufacturing facility, and engineered to express a chimeric antigen receptor that recognises BCMA (B-cell maturation antigen) on myeloma cells. After lymphodepleting chemotherapy, the engineered cells are returned to the patient by intravenous infusion, where they expand, recognise BCMA-positive myeloma cells, and destroy them. What distinguishes equecabtagene autoleucel from earlier BCMA CAR-T products is the design of its binding domain. Many first-generation CAR-T therapies, in myeloma and other cancers, used antibody fragments derived from mouse antibodies. Mouse-derived sequences can sometimes trigger immune reactions in human patients, which may shorten how long the engineered cells persist and reduce the durability of response. Equecabtagene autoleucel uses a fully human single-chain antibody binding domain, designed to reduce this risk. In published clinical data the product has shown high response rates, deep responses including stringent complete remission, and meaningful progression-free intervals in heavily pre-treated patients.

Equecabtagene autoleucel received marketing approval from China's NMPA for relapsed or refractory multiple myeloma based on registrational clinical trial data conducted in Chinese centres. It is one of the first BCMA-directed CAR-T products approved in China specifically for myeloma, joining a small global group that includes idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti), which are approved in the United States, Europe, Japan, and other markets but not all of them in China. The Chinese approval has practical implications for international patients. Approved status means the product is delivered through commercial channels rather than only through clinical trials, with established pricing, treatment protocols, and a network of qualified hospitals authorised to administer it. Trial-stage CAR-T platforms in China continue to operate alongside, but equecabtagene autoleucel offers a clearer regulatory and operational framework for patients who prefer that pathway.

Step 1 — Eligibility Assessment The treating haematology team reviews diagnosis, prior therapy lines, current disease status, organ function, and infection status. Bone marrow assessment, imaging, and laboratory work are updated to confirm active disease, BCMA expression where required, and overall fitness for cell therapy. Step 2 — T Cell Collection T cells are collected by leukapheresis, a procedure similar to a blood donation that takes a few hours. The collected cells are shipped to the manufacturing facility for engineering. Step 3 — Manufacturing The product is manufactured to the patient's specifications, typically over two to four weeks. During this window, patients with rapidly progressing disease may receive bridging therapy to maintain control until infusion. Step 4 — Lymphodepletion The patient is admitted, usually receives three days of fludarabine and cyclophosphamide chemotherapy, and then waits for the engineered cells to arrive. Step 5 — Infusion Equecabtagene autoleucel is given as a single intravenous infusion. Patients are admitted for monitoring during the high-risk window, typically two to four weeks, with close attention to cytokine release syndrome, neurotoxicity, prolonged cytopenias, and infections. Step 6 — Follow-Up After discharge, patients enter a structured follow-up programme that monitors disease response, blood counts, infections, antibody levels, and B-cell aplasia. IVIG replacement may be needed, and CancerFax helps coordinate continuity of follow-up after returning home.

Eligibility is always reviewed by the treating hospital and depends on multiple factors:

• Confirmed diagnosis of multiple myeloma with measurable dise

  Confirmed diagnosis of multiple myeloma with measurable disease activity

• Prior exposure to at least three lines of therapy, generally

  Prior exposure to at least three lines of therapy, generally including a proteasome inhibitor (e.g. bortezomib, carfilzomib), an immunomodulatory drug (e.g. lenalidomide, pomalidomide), and often an anti-CD38 antibody (e.g. daratumumab)

• BCMA expression on myeloma cells, where required by the prot

  BCMA expression on myeloma cells, where required by the protocol

• Adequate organ function — heart, liver, kidney, lung — with

  Adequate organ function — heart, liver, kidney, lung — with attention to renal function which is often impaired in myeloma

• Acceptable blood counts and bone marrow reserve for lymphode

  Acceptable blood counts and bone marrow reserve for lymphodepletion

• ECOG performance status, typically 0 to 2

  ECOG performance status, typically 0 to 2

• No clinically significant CNS disease, or treated and stable

  No clinically significant CNS disease, or treated and stable CNS disease in selected protocols

• No active uncontrolled infection, including hepatitis B, hep

  No active uncontrolled infection, including hepatitis B, hepatitis C, or HIV outside protocol allowances

• Sufficient T-cell counts for manufacturing and ability to to

  Sufficient T-cell counts for manufacturing and ability to tolerate lymphodepleting chemotherapy

• Travel fitness and a realistic plan for several weeks of in-

  Travel fitness and a realistic plan for several weeks of in-country care, plus possible bridging therapy during the manufacturing window

Equecabtagene autoleucel shares the general side effect profile of BCMA-directed CAR-T therapies. The most clinically important effects to plan for include: Side effects are managed by experienced cell therapy units using established protocols. Major Chinese centres administering equecabtagene autoleucel have ICU-level support, integrated infection management, and structured follow-up programmes.

• Cytokine release syndrome (CRS) — the most common early effe

  Cytokine release syndrome (CRS) — the most common early effect, typically beginning within the first week after infusion, managed with paracetamol, fluids, oxygen, tocilizumab, and steroids as needed

• Immune effector cell-associated neurotoxicity syndrome (ICAN

  Immune effector cell-associated neurotoxicity syndrome (ICANS) — confusion, word-finding difficulty, tremor, drowsiness, or in severe cases seizures; managed mainly with steroids

• Prolonged cytopenias — low blood counts that can persist for

  Prolonged cytopenias — low blood counts that can persist for weeks to months, requiring transfusions, growth factor support, and infection prevention

• Infections — bacterial, viral, and rarely fungal infections

  Infections — bacterial, viral, and rarely fungal infections during and after the high-risk window

• Hypogammaglobulinemia — low antibody levels due to loss of n

  Hypogammaglobulinemia — low antibody levels due to loss of normal plasma cells and B cells, often requiring IVIG replacement for months to years

• Rare but important risks include macrophage activation syndr

  Rare but important risks include macrophage activation syndrome (HLH), severe coagulopathy, and rare cardiac or organ events

This comparison is general and is not a recommendation of one product over another. The right choice depends on diagnosis details, prior therapy, country of residence, regulatory access, cost, and the treating team's experience with each product. CancerFax helps patients understand which option is realistically available for their situation.

Equecabtagene autoleucel is administered at qualified Chinese cancer hospitals and academic haematology centres authorised by the manufacturer and the regulatory framework. This includes leading institutions in Beijing, Shanghai, Guangzhou, Tianjin, and other major cities. Authorised centres typically have established cell therapy units, ICU support, integrated infection management, and the experience needed to manage CRS, ICANS, and prolonged cytopenias. Trial-stage CAR-T platforms continue to operate alongside, and at some hospitals patients may be considered for either approved or trial-stage products depending on their situation. International patient access depends on the centre's experience with foreign cases, language support, and admission capacity. CancerFax helps match patients with appropriate centres rather than recommending a single hospital.

Frequently Asked Questions

Answers to common questions from patients and families.

This guide is for patient education and care navigation support only. It is not an official communication of the manufacturer of equecabtagene autoleucel and does not represent product labelling. Approval status, indications, pricing, hospital authorisation, and treatment availability change over time. The treating hospital and the most recent regulatory and product information remain the operational reference. This page does not replace medical advice from a qualified oncologist or haematologist. Eligibility, treatment choice, response, side effects, cost, and outcomes vary from patient to patient. CancerFax does not provide emergency medical care. Patients with breathing difficulty, severe bleeding, seizures, sudden weakness, uncontrolled pain, fever during treatment, or rapidly worsening symptoms should contact their treating hospital or emergency services immediately.

Structured reference data summarizing key information for this topic.

Structured reference data summarizing key information for this topic.